Pharmafile Logo
Pharmafocus logo
Advanced Search

ACS

Showing 12 posts of 12 posts found.

Sanofi image

Sanofi diabetes drug fails to show cardio disease benefit

March 19, 2015
Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes

A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …

News
Lilly image

German court rules against Lilly in Alimta patent case

March 10, 2015
Manufacturing and Production, Sales and Marketing ACS, Actavis, Alimta, NICE, NSCLC, lilly, lung cancer, pemetrexed

A German court has ruled that Lilly’s patent for its lung cancer drug Alimta would not be infringed by generic …

News
Xarelto image

NICE recommends Bayer heart attack drug

January 26, 2015
Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban

NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …

News
Lilly image

NICE extends recommendation for Efient

July 24, 2014
Sales and Marketing ACS, Efient, NICE, Plavix, longs ton, prasugrel

In updated guidance NICE has extended its recommendation of Efient (prasugrel) in combination with aspirin for preventing blood clots in …

News
Xarelto, bayer, ACS, janssen, fda, asa, blood

Bayer ‘disappointed’ with FDA

February 18, 2014
Sales and Marketing ACS, Bayer, Xarelto, blood, rivaroxaban

Bayer HealthCare has expressed its dismay after the Food and Drug Administration once again rejected further indications for the company’s …

News
Xarelto image

Xarelto gets ACS indication

May 29, 2013
Sales and Marketing ACS, Bayer, Xarelto

Bayer HealthCare’s bloodthinner Xarelto has expanded its reach in Europe with approval for secondary prevention after an acute coronary syndrome …

News

Pharma manufacturing news in brief

February 4, 2013
Manufacturing and Production ACS, Amcor, Beanne, Iogen Bio-products, Novozymes, Pluristem

Facility investments from Amcor and Pluristem, Beanne Chemical falls foul of FDA inspectors, Novozymes acquisition plus a green chemistry app.

News
Xarelto image

FDA rejects licence extension for Xarelto

June 26, 2012
Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto

The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …

News

Merck’s vorapaxar fails in late-stage trial

November 15, 2011
ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar

Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …

News

Brilique gains NICE approval

October 31, 2011
Sales and Marketing ACS, Brilique, NICE, Plavix, clopidogrel

AstraZeneca’s Brilique has been approved by NICE for use in combination with aspirin as an option to treat patients with …

News

Merck suffers late-stage blow to vorapaxar

January 18, 2011
Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar

An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …

News

Apixaban trial for ACS abandoned

October 20, 2010
Sales and Marketing ACS, BMS, Pfizer, apixaban

  Pfizer and Bristol-Myers Squibb have halted a trial of their heart drug apixaban after signs of increased risk of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025